Synthesis of an iodine-123-labeled celecoxib analogue: A potential spect agent

Journal of Labelled Compounds and Radiopharmaceuticals

Volumn 48, Issue 4, 2005, Pages 295-300

  Kabalka, George W ^a   Mereddy, Arjun R ^a   Schuller, Hildegard M ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

Author keywords

Celecoxib; Colon cancer; Radio TLC; Radioiodination; SPECT

Indexed keywords

PARTICLE BEAMS; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY;

4-METHYLPHENYL; BENZENESULFONAMIDE; CELECOXIB; COLON CANCER; CYCLOOXYGENASE 2; IODINE-123; RADIO-TLC; RADIOIODINATION; SINGLE PHOTONS; SPECT;

IODINE;

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; IODINE 123; PALLADIUM;

ALZHEIMER DISEASE; ARACHIDONIC ACID METABOLISM; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CHEMICAL STRUCTURE; COLON CANCER; DIAGNOSTIC IMAGING; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOCHEMISTRY; RADIOIODINATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYNTHESIS;

EID: 17444431148     PISSN: 03624803     EISSN: None     Source Type: Journal    
DOI: 10.1002/jlcr.923     Document Type: Article

References (22)

1. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T, Takahashi T. Cancer Res 1998; 58: 3761-3764.
2. Hong SH, Avis I, Vox MD, Martinez A, Treston AM, Mulshine JL. Cancer Res 1999; 59: 2223-2228.
3. Back SJ, Kim KS, Nixon JB, Wilson LLC, Eling TE. Mol Pharmacol 2001; 59: 901-909.
4. Castonguay A, Rioux N, Duperron C, Jalbert G. Exp Lung Res 1998; 24: 605-615.
5. Harris RE, Beebe-Donk J, Schuller HM. Oncol Rep 2002; 9: 693-695.
6. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA. Cancer Res 1999; 59: 4356-4362.
7. Schuller HM, Weddle DL, Zhang L, Walker K, Miller MS, Castonguay A. Proc Am Assoc Cancer Res 2002; 43: 3201.
8. Rioux N, Castonguay A. Cancer Res 1998; 58: 5354-5360.
9. Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn Jr Pa, Chou TC. Cancer Res 1999; 59: 6178-6184.
10. Weddle DL, Tithoff P, Williams M, Schuller HM. Carcinogenesis 2001; 22: 473-479.
11. Schuller HM, Tithof PK, Williams M, Plummer III H. Cancer Res 1999; 59: 4510-4515.
12. Cakir Y, Plummer III HK, Tithof PK, Schuller HM. Int J Oncol 2002; 21: 153-157.
13. Koehne CH, Dubois RM. Semin Oncol 2004; 31: 12-21.
14. Roberts EG, Vona-Davis L, Riggs DR, Jackson BJ, Hohseni H, Kandzari SJ, McFadden DW. W Va Med J 2004; 100: 96-101.
15. Fenton C, Keating GM, Wagstaff AJ. Drugs 2004; 64: 1231-1261.
16. Wigand R, Wehling M, Brauer HG, Stridde E, Vergin H, May M. Deut Med Wochenschr 2004; 129: 1188-1192.
17. Hoozemans JJ, Veerhuis R, Rozemuller AJ, Eikelenboom P. Curr Drug Targets 2003; 4: 461-468.
18. Walker T. J Obstet Gynaecol 1999; 19: 56-58.
19. Krum H, Liew D, Aw J, Haas S. Expert Rev Cardiovasc Ther 2004; 2: 265-270.
20. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Lancet 2004; 364 (early online publication).
21. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, Anderson GD, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY, Isakson PC. J Med Chem 1997; 40: 1347-1365.
22. Akula MR, Kabalka GW. J Label Compd Radiopharm 1999; 42: 959-964.